Recent developments in the treatment of advanced bladder cancer

James Luke Godwin, Jean Hoffman-Censits, Elizabeth Plimack

Research output: Contribution to journalReview article

Abstract

Urothelial carcinoma of the bladder is a common malignancy which has historically been difficult to treat in its advanced stages. Clinically effective treatment options for locally advanced/inoperable or metastatic urothelial carcinoma (mUC) consisted of cisplatin-based chemotherapy regimens, with few other impactful therapeutic options. The past 2 years have seen a remarkable shift in the therapeutic landscape of mUC, with 5 novel immunotherapy agents receiving FDA approval for mUC, including first-line and second-line postplatinum settings. There are now many important clinical trials ongoing seeking to answer how best to use chemotherapy, immunotherapy, and targeted therapy agents in patients with mUC. Here we review the current standard of care for patients with mUC based on published data from the past 2 years, and look forward toward future research directions.

Original languageEnglish (US)
Pages (from-to)109-114
Number of pages6
JournalUrologic Oncology: Seminars and Original Investigations
Volume36
Issue number3
DOIs
StatePublished - Mar 1 2018
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Carcinoma
Immunotherapy
Therapeutics
Drug Therapy
Proxy
Standard of Care
Cisplatin
Urinary Bladder
Clinical Trials
Neoplasms

Keywords

  • Bladder cancer
  • Checkpoint inhibitors
  • Chemotherapy
  • Clinical trials
  • Immunotherapy
  • Platinum ineligible
  • Targeted therapy
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Recent developments in the treatment of advanced bladder cancer. / Godwin, James Luke; Hoffman-Censits, Jean; Plimack, Elizabeth.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 36, No. 3, 01.03.2018, p. 109-114.

Research output: Contribution to journalReview article

@article{0e0e2098a7c4447c85e86436d4515ab1,
title = "Recent developments in the treatment of advanced bladder cancer",
abstract = "Urothelial carcinoma of the bladder is a common malignancy which has historically been difficult to treat in its advanced stages. Clinically effective treatment options for locally advanced/inoperable or metastatic urothelial carcinoma (mUC) consisted of cisplatin-based chemotherapy regimens, with few other impactful therapeutic options. The past 2 years have seen a remarkable shift in the therapeutic landscape of mUC, with 5 novel immunotherapy agents receiving FDA approval for mUC, including first-line and second-line postplatinum settings. There are now many important clinical trials ongoing seeking to answer how best to use chemotherapy, immunotherapy, and targeted therapy agents in patients with mUC. Here we review the current standard of care for patients with mUC based on published data from the past 2 years, and look forward toward future research directions.",
keywords = "Bladder cancer, Checkpoint inhibitors, Chemotherapy, Clinical trials, Immunotherapy, Platinum ineligible, Targeted therapy, Urothelial carcinoma",
author = "Godwin, {James Luke} and Jean Hoffman-Censits and Elizabeth Plimack",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.urolonc.2017.12.018",
language = "English (US)",
volume = "36",
pages = "109--114",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Recent developments in the treatment of advanced bladder cancer

AU - Godwin, James Luke

AU - Hoffman-Censits, Jean

AU - Plimack, Elizabeth

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Urothelial carcinoma of the bladder is a common malignancy which has historically been difficult to treat in its advanced stages. Clinically effective treatment options for locally advanced/inoperable or metastatic urothelial carcinoma (mUC) consisted of cisplatin-based chemotherapy regimens, with few other impactful therapeutic options. The past 2 years have seen a remarkable shift in the therapeutic landscape of mUC, with 5 novel immunotherapy agents receiving FDA approval for mUC, including first-line and second-line postplatinum settings. There are now many important clinical trials ongoing seeking to answer how best to use chemotherapy, immunotherapy, and targeted therapy agents in patients with mUC. Here we review the current standard of care for patients with mUC based on published data from the past 2 years, and look forward toward future research directions.

AB - Urothelial carcinoma of the bladder is a common malignancy which has historically been difficult to treat in its advanced stages. Clinically effective treatment options for locally advanced/inoperable or metastatic urothelial carcinoma (mUC) consisted of cisplatin-based chemotherapy regimens, with few other impactful therapeutic options. The past 2 years have seen a remarkable shift in the therapeutic landscape of mUC, with 5 novel immunotherapy agents receiving FDA approval for mUC, including first-line and second-line postplatinum settings. There are now many important clinical trials ongoing seeking to answer how best to use chemotherapy, immunotherapy, and targeted therapy agents in patients with mUC. Here we review the current standard of care for patients with mUC based on published data from the past 2 years, and look forward toward future research directions.

KW - Bladder cancer

KW - Checkpoint inhibitors

KW - Chemotherapy

KW - Clinical trials

KW - Immunotherapy

KW - Platinum ineligible

KW - Targeted therapy

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85040976808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040976808&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2017.12.018

DO - 10.1016/j.urolonc.2017.12.018

M3 - Review article

C2 - 29395952

AN - SCOPUS:85040976808

VL - 36

SP - 109

EP - 114

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 3

ER -